Foghorn Therapeutics (FHTX) Net Margin (2020 - 2026)

Foghorn Therapeutics' Net Margin history runs 7 years deep, the most recent figure standing at 2468.38% for Q1 2026.

• In Q1 2026, Net Margin fell 208224.0% year-over-year to 2468.38%; the TTM figure through Mar 2026 stood at 800.84% (down 44096.0% YoY), while the FY2025 annual figure was 858.26%, down 47502.0% from the prior year.
• Net Margin for Q1 2026 stood at 2468.38%, down from 257.91% in the prior quarter.
• The five-year high for Net Margin was 82.07% in Q3 2023, with the low at 2468.38% in Q1 2026.
• The 5-year median for Net Margin is 512.09% (2025), against an average of 612.45%.
• The sharpest annual moves came in 2022 and 2026: Net Margin jumped 24430424 bps in 2022, then tumbled 208224 bps in 2026.
• Foghorn Therapeutics' Net Margin stood at 690.39% in 2022, then soared by 39 bps to 417.85% in 2023, then sank by 63 bps to 682.88% in 2024, then jumped by 62 bps to 257.91% in 2025, then tumbled by 857 bps to 2468.38% in 2026.
• Business Quant data shows FHTX's Net Margin at 2468.38% in Q1 2026, 257.91% in Q4 2025, and 512.09% in Q3 2025.